Chemistry Seminar: D112 Synthesis
D112 Synthesis
Bryan Zych
Chemistry MS Candidate
School of Chemistry and Materials Science, RIT
Abstract:
Extensive research is being done to solve the problems that come with cancer and cancer treatments. A large problem with cancer treatments is the non-selective toxicity of the compounds used. D112 has shown selectivity in terms of tumor cell deaths to healthy cell deaths at a rate of 900:1 where chemotherapy is currently 2:1. D112 acts as a drug in photodynamic therapy to reduce tumor mass and restore apoptosis in cells. This compound is now generated through a new synthetic route. Understanding the synthetic route and how apoptosis is restored to the cells is important to further research on the molecule and improving its selectivity to reduce tumor mass.
Speaker Bio:
Bryan Zych is from Scotia, New York. Bryan attended Syracuse University in 2016 and received a Bachelor of Science in medicinal chemistry in 2020. Bryan is now working with Dr. Jeremy Cody on D112 synthesis here at RIT. Bryan is an MS student and currently set to receive a diploma in May 2022.
Intended Audience:
Undergraduates, graduates, and experts. Those with interest in the topic.
Event Snapshot
When and Where
Who
This is an RIT Only Event
Interpreter Requested?
No